Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | HRH1 | P35367 | 1/20 | 0.82 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | BACE1 | P56817 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970484 | 0.98 | LTA4H (0.97) | LTA4HHRH3KCNH2HRH1HRH4 | |
| SCHEMBL4094594 | 0.92 | HRH3 (1.00) | LTA4HHRH3KCNH2HRH1HRH4 | |
| SCHEMBL10679417 | 0.90 | HRH3 (0.97) | LTA4HHRH3KCNH2HRH1HRH4 | |
| SCHEMBL491626 | 0.90 | HRH3 (1.00) | LTA4HHRH3KCNH2HRH1HRH4 | |
| SCHEMBL255201 | 0.89 | LTA4H (0.86) | LTA4HHRH3BACE1 | |
| SCHEMBL492265 | 0.89 | HRH3 (0.97) | LTA4HHRH3KCNH2HRH1HRH4 | |
| SCHEMBL10676754 | 0.89 | HRH3 (0.97) | LTA4HHRH3KCNH2HRH1HRH4 | |
| Ammonia Solution, Strong SCHEMBL264615 | 0.87 | LTA4H (0.83) | LTA4HHRH3BACE1 | |
| SCHEMBL3951411 | 0.87 | LTA4H (0.83) | LTA4HHRH3KCNH2HRH1BACE1 | |
| SCHEMBL5870409 | 0.87 | LTA4H (0.83) | LTA4HHRH3KCNH2HRH1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009105723-A2 | NOVEL METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2009-08-27 | — | — | WO | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20110105959-A1 | Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2009105723-A2 | NOVEL METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-0980367-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-0993300-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001085166-A1 | METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS | CREIGHTON UNIVERSITY (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-0993300-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0980367-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1998048798-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049161-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | LTA4H 6/4885HRH3 5/4885KCNH2 688/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | LTA4H 6/4885HRH3 5/4885KCNH2 688/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | LTA4H 2/4885HRH3 2276/4885KCNH2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.